

Feng-Xia Sun, De-Cai Fu* and
Yi-Feng YuCollege of Chemical and Pharmaceutical
Engineering, Hebei University of Science and
Technology, Shijiazhuang 050018, People's
Republic of China

Correspondence e-mail: fxsun001@163.com

Key indicators

Single-crystal X-ray study
 $T = 113$ K
Mean $\sigma(\text{C}-\text{C}) = 0.002$ Å
Disorder in solvent or counterion
 R factor = 0.044
 wR factor = 0.120
Data-to-parameter ratio = 14.7For details of how these key indicators were
automatically derived from the article, see
<http://journals.iucr.org/e>.3-(Benzotriazol-1-yl) 5-ethyl 2,6-dimethyl-
4-(3-nitrophenyl)-1,4-dihydropyridine-
3,5-dicarboxylate ethyl acetate hemisolvateThe title compound, $\text{C}_{23}\text{H}_{21}\text{N}_5\text{O}_6 \cdot 0.5\text{C}_4\text{H}_8\text{O}_2$, is an important
intermediate in the synthesis of nefidipine-type pharmaceu-
ticals. The crystal packing is stabilized by intermolecular $\text{N}-$
 $\text{H} \cdots \text{O}$ hydrogen bonds.Received 2 August 2006
Accepted 21 August 2006

Comment


4-Aryl-1,4-dihydropyridine-3,5-dicarboxylic diesters of the
nefidipine type have become almost indispensable in the
treatment of cardiovascular diseases since they first appeared
on the market in 1975 (Yiu & Knaus, 1999; Goldmann &
Stoltefuss, 1991). The title compound, (I), is a key inter-
mediate in their preparation.

Fig. 1 shows the structure of (I). The dihydropyridine ring has a flattened boat conformation. This compares well with the structures of 3-(benzotriazol-1-yl)-5-*tert*-butyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate and nefidipine (Liu *et al.*, 2006; Hofmann & Cimraglia, 1990; Ramusino & Vari, 1999). The ethyl acetate solvent was found to be disordered across an inversion center.

The crystal packing is stabilized by intermolecular $\text{N}-$
 $\text{H} \cdots \text{O}$ hydrogen bonds (see Table 2), which link the molecules into chains running parallel to the a axis.

Experimental

The title compound was prepared by dissolving 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid monoethyl ester (346 mg, 1 mmol) in 28 ml CH_2Cl_2 with dicyclohexyl carbodiimide (206 mg, 1 mmol). Benzotriazol-1-ol (135 mg, 1 mmol) in 10 ml CH_2Cl_2 was added dropwise to this solution at 278 K. The reaction

mixture was stirred at 276–279 K for a further 6 h. The solvent, CH₂Cl₂, was removed by vacuum evaporation at 293 K. The desired compound was purified by chromatography on a silica gel column (eluted by ethyl acetate and petroleum, 1:5) at room temperature. The product (430 mg) was obtained in a yield of 93%. Suitable crystals were obtained by slow evaporation of an ethyl acetate solution.

Crystal data

C₂₃H₂₁N₅O₆·0.5C₄H₈O₂ Z = 4
 M_r = 507.50 D_x = 1.347 Mg m⁻³
 Monoclinic, P2₁/n Mo Kα radiation
 a = 10.2988 (13) Å μ = 0.10 mm⁻¹
 b = 17.092 (2) Å T = 113 (2) K
 c = 14.2211 (17) Å Block, colorless
 β = 90.162 (4)° 0.22 × 0.18 × 0.14 mm
 V = 2503.2 (5) Å³

Data collection

Rigaku Saturn diffractometer 22057 measured reflections
 ω scans 5438 independent reflections
 Absorption correction: multi-scan 4048 reflections with I > 2σ(I)
 (Jacobson, 1998) R_{int} = 0.046
 T_{min} = 0.973, T_{max} = 0.986 θ_{max} = 27.0°

Refinement

Refinement on F² w = 1/[σ²(F_o²) + (0.0708P)²]
 R[F² > 2σ(F²)] = 0.044 where P = (F_o² + 2F_c²)/3
 wR(F²) = 0.120 (Δ/σ)_{max} = 0.001
 S = 1.02 Δρ_{max} = 0.29 e Å⁻³
 5438 reflections Δρ_{min} = -0.32 e Å⁻³
 370 parameters Extinction correction: SHELXL97
 H atoms treated by a mixture of Extinction coefficient: 0.0196 (16)
 independent and constrained refinement

Table 1

Selected geometric parameters (Å, °).

O1–N1	1.3718 (14)	N2–N3	1.3113 (17)
N1–N2	1.3448 (17)		
N2–N1–O1	119.47 (11)	N3–N2–N1	106.98 (11)

Table 2

Hydrogen-bond geometry (Å, °).

D–H···A	D–H	H···A	D···A	D–H···A
N4–H4A···O5 ⁱ	0.86 (2)	2.17 (2)	2.9770 (18)	157.4 (18)

Symmetry code: (i) x – 1, y, z.

All C-bound H atoms were positioned geometrically and refined using a riding model, with C–H = 0.97 Å and U_{iso}(H) = 1.2U_{eq}(C).




Figure 1

A view of the title compound (I), showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 30% probability level and H atoms are shown as small spheres of arbitrary radii.

The H atom on N4 was located in a difference Fourier map and was refined isotropically. The disordered ethyl acetate molecule is located on an inversion center. The C=O double bond was restrained to 1.26 (1) Å, while the C–O and C–C single bonds were restrained to 1.42 (1) and 1.52 (1) Å, respectively. The bond angles were also restrained by restraining the 1–3 atom distances.

Data collection: *CrystalClear* (Rigaku, 2005); cell refinement: *CrystalClear*; data reduction: *CrystalClear*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *SHELXTL* (Bruker, 1997); software used to prepare material for publication: *CrystalStructure* (Rigaku/MS, 2005).

The authors gratefully acknowledge support from Nankai University and Hebei University of Science and Technology.

References

Bruker (1997). *SHELXTL*. Bruker AXS Inc., Madison, Wisconsin, USA.
 Goldmann, S. & Stoltefuss, J. (1991). *Angew. Chem. Int. Ed. Engl.* **30**, 1559–1578.
 Hofmann, H. J. & Cimraglia, R. (1990). *J. Mol. Struct. (Theochem)*, **205**, 1–11.
 Jacobson, R. (1998). Private communication to Rigaku Corporation, Tokyo, Japan.
 Liu, B.-S., Sun, F.-X., Zhou, L.-N., Sun, H. & Wang, J.-K. (2006). *Acta Cryst. E* **62**, o72–o73.
 Ramusino, M. C. & Vari, M. R. (1999). *J. Mol. Struct. (Theochem)*, **492**, 257–268.
 Rigaku (2005). *CrystalClear*. Version 1.36. Rigaku Corporation, Tokyo, Japan.
 Rigaku/MS (2005). *CrystalStructure*. Version 3.7.0. Rigaku/MS Inc., The Woodlands, Texas, USA.
 Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
 Yiu, S. H. & Knaus, E. E. (1999). *Drug Dev. Res.* **48**, 26–37.